Adjuvant Treatment with Atezolizumab and Bevacizumab May Delay Recurrence After Surgical Resection in Patients with Liver Cancer; Results of Landmark Study May Prove Practice-Changing; Study Presented at AACR 2023

Adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) increased recurrence-free survival of patients with hepatocellular carcinoma (HCC) following surgical resection or ablation, according to the results from the phase III IMbrave050 clinical trial, which were presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19 in Orlando, Florida.

Login Or Register To Read Full Story